阿斯利康 2024年年度报告-临床研究附录-Clinical Trials Appendix FY 2024 Results Update.docx

ClinicalTrials

Appendix

FY2024ResultsUpdate

6February2025

19119Pipeline

191

19

projectsinourdevelopmentpipelinenewmolecularentities(NME)

projectsinour

developmentpipeline

newmolecularentities(NME)inourlate-stagepipeline

130newmolecularentities(NME)ormajorlifecyclemanagement(LCM)

130

newmolecularentities

(NME)ormajorlifecycle

management(LCM)projectsinPhaseIIandPhaseIII

31

regulatoryapprovalsinmajormarkets

sinceFY2023

2

Acrossfivefocustherapyareas:

Oncology

BioPharmaceuticals

CVRM|RI|VI

RareDisease

Asof6February2025.Appendix:Glossary.

Keyupcomingpipelinecatalysts:2025and2026

OncologyBioPharmaceuticalsRareDisease

H22025

H22025

2026

H12025

Calquence-MCL(1L)(ECHO)(EU,JP)Calquence-CLL(1Lfixedduration)(AMPLIFY)Imfinzi-early-stageNSCLC(perioperative)(AEGEAN)(JP)Imfinzi-limited-stageSCLC(ADRIATIC)(EU,CN)Enhertu

Calquence-MCL(1L)(ECHO)(EU,JP)

Calquence-CLL(1Lfixedduration)(AMPLIFY)

Imfinzi-early-stageNSCLC(perioperative)(AEGEAN)(JP)Imfinzi-limited-stageSCLC(ADRIATIC)(EU,CN)

Enhertu-HER2-lowandultralowmet.breastcancer(DESTINY-Breast06)(JP)Truqap-HR+HER2-met.breastcancer(2L)(CAPItello-291)(CN)

Datroway-HR+HER2-breastcancer(2L+)(TROPION-Breast01)(CN)Datroway-EGFRmNSCLC(laterline)(TROPION-Lung05)

Ultomiris-NMOSD(CHAMPION-NMOSD)(CN)Koselugo-adultNF1-PN(KOMET)

Imfinzi+Imjudo-NSCLC(1L)(POSEIDON)(CN)Tezspire-severeasthma(DIRECTION)(CN)

Wainua-ATTRv-PN(NEURO-TTRansform)(CN)

Imfinzi-muscle-invasivebladdercancer(NIAGARA)

Regulatorydecision1,2Enhertu-HER2-lowand-ultralowmet.breastcancer(DESTINY-Breast06)(EU)Datroway-HR+HER2-met.breastcancer

Regulatorydecision1,2

Wainua-ATTRv-PN(NEURO-TTRansform)(EU)Ultomiris-gMG(CHAMPION-MG)(CN)

acoramidis-ATTR-CM(ALXN2060-TAC-302)(JP)

KeyPhaseIIIdatareadouts

Enhertu-high-riskHER2+earlybreastcancer(neoadj.)(DEST